--- title: Daytime vs. Delayed Eating Among Obese Individuals nct_id: NCT03354169 overall_status: COMPLETED phase: NA sponsor: University of Pennsylvania study_type: INTERVENTIONAL primary_condition: Obesity countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03354169.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03354169" ct_last_update_post_date: 2025-11-21 last_seen_at: "2026-05-12T06:19:53.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Daytime vs. Delayed Eating Among Obese Individuals **Official Title:** Randomized Controlled Trial Examining the Effects of Meal Timing Among Obese Individuals **NCT ID:** [NCT03354169](https://clinicaltrials.gov/study/NCT03354169) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 38 - **Lead Sponsor:** University of Pennsylvania - **Collaborators:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - **Conditions:** Obesity - **Start Date:** 2018-02-07 - **Completion Date:** 2023-03-02 - **CT.gov Last Update:** 2025-11-21 ## Brief Summary The randomized, cross-over design study is designed to determine how timing of eating affects weight, adiposity, energy metabolism, and gene expression. Obese participants will be provided isocaloric meals and snacks to be consumed in one of two prescribed eating conditions -- daytime eating and delayed eating. ## Detailed Description The study consists of the following phases - screening, assessment visit 1, eating condition 1, assessment visit 2, a wash-out period, assessment visit 3, eating condition 2 and assessment visit 4, as discussed in detail below. The assessment visits will all consist of the same procedures and will take place at the Center for Human Phenomic Science (CHPS) of the Hospital of the University of Pennsylvania before and after each of the eating conditions (four times total). The four 28-hour inpatient assessments will consist of blood draws, adipose (fat) tissue sampling, a dual energy X-ray absorptiometry (DEXA) scan, and a resting metabolic rate test. During the screening period in order to determine eligibility, participants must complete a 2-part screening visit; This includes: 1. A complete physical examination 2. Tests of blood to screen for any conditions such as diabetes or any serious, uncontrolled medical condition that may interfere with participation in the study. 3. An Electrocardiogram (EKG) test 4. Urine Pregnancy Test 5. Urine Drug Screening 6. the completion of several self-report questionnaires and structured interviews During the screening period, participants will also be asked to keep a 10-day food log where they will record all food and beverages consumed and their sleep and exercise schedule. Participants will be asked to wear an Actigraph wrist watch at this time. Following successful completion of the screening period, participants will complete the first of 4 assessment visits. All assessment visits will follow the same protocol. Assessment Visit Day 1 Procedures: The visit will include 28 hours (overnight) spent at the CHPS, where meals and snacks will be provided. At each of the assessment visits participants will be given a urine drug screening and, if appropriate, a pregnancy test. The lights will be dim in the hospital room to control for light. Participants will arrive at 7:00 am. Starting at 8:00 am, blood will be drawn every four hours. From this blood gene expression and hormones related to metabolism, eating, and sleep will be measured. Following the first blood draw, resting metabolic rate is measured for 45 minutes. Lunch is then provided, followed by a measurement of body composition using a DEXA scan. Next, the adipose tissue sampling procedure will begin. Lastly, the participants will complete a series of cognitive tests administered on a laptop. Participants will be provided meals and snacks during their visit and are free to watch television or participate in other sedentary pastimes while they are there. Assessment Visit Day 2 Procedures: After an overnight fast, participants will undergo the Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT) on the morning of day 2. Following the FSIGT test, participants will be served a meal and during the first assessment visit, participants will be randomly assigned to start with one of two eating conditions for the next 8 weeks: 1) Daytime or 2) Delayed. Following randomization, participants will be discharged from CHPS and begin eating condition 1. If participants are assigned to the daytime eating condition first, they will be asked to consume all of their meals and snacks each day between 8:00 am and 7:00 pm. If they are assigned to the delayed eating condition first, they will be asked to consume all of their meals and snacks between 12 noon and 11:00 pm each day. Participants will eat on this schedule for 8 weeks. During the two, 8-week eating periods, all of the meals and snacks will be provided by the research kitchen. During the eating conditions, participants will be asked to complete daily self-report queries concerning their adherence to the food, sleep, and physical activity requirements of the study. Following eating condition 1, participants will return for assessment visit 2. This assessment visit follows the same procedures as all other assessment visits. Following assessment visit 2, participants will begin their 2 week washout period where they are instructed to eat as they normally would whenever they like. Following the two-week washout period, participants will return for assessment visit 3, after which they will begin eating condition 2. Following 8 weeks of eating condition 2 participants will return for their final visit, assessment visit 4. After this final assessment, participation in the study will be complete. ## Eligibility - **Minimum age:** 21 Years - **Maximum age:** 50 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria: * age 21-50 * BMI of 30-50 kg/m2 * stable weight (±10 lb) over the previous 6 months * women must be pre-menopausal with regular menstrual cycles Exclusion Criteria: * unstable, serious medical conditions * use of medicine linked to weight gain/loss * cardiac conditions * cancer * diabetes * autoimmune disease * use of illicit drugs, melatonin, diuretics or hypnotics * involved in a current weight loss program * presence of an untreated sleep disorder (determined by surveys and actigraphy) * those who work shift work * those with extreme chronotypes * habitual waking outside of 0600h-0930h * habitual bedtime \<2200h or \>2400h * sleep duration of \<6.5 or \>8.5 h/night. * psychiatric exclusions will be: depression (Patient Health Questionnaire-9 score ≥9), lifetime bipolar disorder, psychosis, or eating disorder; or any other severe psychiatric disorder judged to interfere with study adherence as assessed by the MINI International Neuropsychiatric Interview. * structured exercise \>3 d/wk, for \>30 min measured by exercise logs and actigraphy; normal activity levels are required during the study (±30 min/wk of baseline level). ``` ## Arms - **Daytime Eating Condition** (EXPERIMENTAL) — Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900. - **Delayed Eating Condition** (EXPERIMENTAL) — Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300. - **Withdrawn before randomization** (OTHER) — Two participants completed the screening process and started the first inpatient assessment visit but were withdrawn prior to completion of the assessment visit and were not randomized to start the intervention. They were not included in data analysis. ## Interventions - **Eating Condition** (BEHAVIORAL) — Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2. - **No Intervention; withdrawn before randomization** (OTHER) — These participants were withdrawn and did not receive an intervention. ## Primary Outcomes - **Body Mass (Weight)** _(time frame: pre-post changes between the daytime and delayed eating conditions (each 8 weeks long))_ — changes in body mass, as measured by a calibrated digital scale, will be explored. - **Adiposity - Total Body Fat** _(time frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).)_ — changes in measures of total body fat, as measured by a DEXA scan, will be explored. - **Energy Homeostasis Outcomes - REE** _(time frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).)_ — Changes in resting energy expenditure values will be explored. - **Energy Homeostasis - Respiratory Quotient** _(time frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).)_ — Respiratory quotient (RQ) was measured with a Parvo-Medics metabolic cart. It is calculated from the ratio of carbon dioxide produced by the body to oxygen consumed by the body, when the body is in a steady state. ## Locations (1) - Center for Weight and Eating Disorders, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.center for weight and eating disorders, perelman school of medicine, university of pennsylvania|philadelphia|pennsylvania|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT03354169.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT03354169* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*